In a discussion with Alicia Morgans, Paul Nguyen highlights the advancing role of predictive biomarkers in prostate cancer treatment. He distinguishes between prognostic and predictive biomarkers, emphasizing the unique value of the latter in tailoring the right amount of treatment for individual patients. They focus on the development of a commercial test by Artera that predicts responses to short-term androgen deprivation therapy (ADT) among intermediate-risk patients, helping determine the appropriateness of such treatment. Dr. Nguyen discusses the significant influence of integrating AI with digital pathology to create a robust biomarker model. Moving forward, they discuss a recent study examining long-term versus short-term ADT in high-risk patients, finding a biomarker to identify who would benefit from extended treatment. Dr. Nguyen is optimistic about the transformative potential of these biomarkers, marking a shift towards precision treatment in prostate cancer care.

Biographies:

Paul Nguyen, MD, Genitourinary Clinical Center Director, Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 

Alicia Morgans, MD, MPH, Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts